Nippon Chemiphar Co Ltd

Chart & Performance

D1W1MN

P/E

—

P/S

0.18

EPS

—

Div Yield, %

3.34%

Shrs. gr., 5y

0.07%

Rev. gr., 5y

-2.10%

Revenues

30.75b

-2.57%

Net income

-180m

CFO

296m

Dividend

Mar 28, 20250 JPY/sh

Profile

Nippon Chemiphar Co., Ltd., together with its subsidiaries, manufactures, markets, imports, exports, and sells, ethical pharmaceuticals and diagnostic agents in Japan and internationally. It offers diagnostic products, such as IgE NC, a diagnostic kit that provides results and reveals total IgE levels, as well as 57 individual allergen reagents; and DP3000, a device for allergen-specific IgE measurements. The company also develops NC-2400, a PPAR-delta agonist; NC-2500, a novel advanced xanthine oxidoreductase inhibitor for the treatment of hyperuricemia/gout; and NC-2600, a P2X4 receptor antagonist for the treatment of neuropathic pain. In addition, it develops NC-2700, a novel urate transporter 1 inhibitor that enhance excretion urate to urine; NC-2800, a delta opioid receptor agonist for the treatment of depression/anxiety; Uralyt-U, an alkalization therapeutic drug; Soleton, an analgesic and anti-inflammatory drug; and Calvan, a hypertension therapeutic drug. Further, the company provides quasi-drugs, nutrients, health foods, cosmetics, and various type of creams. It distributes its generic pharmaceuticals through wholesalers to hospitals and pharmacies. The company was formerly known as Hitachi Chemical Co., Ltd. and changed its name to Nippon Chemiphar Co., Ltd. in 1970. Nippon Chemiphar Co., Ltd. was founded in 1950 and is headquartered in Tokyo, Japan.

URL

https://www.chemiphar.co.jp/

IPO date

Oct 01, 1971

Employees

872

Domiciled in

Incorporated in

Valuation

Order:

Title JPY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title JPY in thousands, except ratios and share amounts	2024‑03	2023‑03	2022‑03	2021‑03	2020‑03	2019‑03	2018‑03	2017‑03	2016‑03	2015‑03
Income
Revenues	30,748,000 -2.57%	31,559,000 -2.91%	32,506,000 3.06%
Cost of revenue	31,242,000	31,799,000	31,680,000
Unusual Expense (Income)
NOPBT	(494,000)	(240,000)	826,000
NOPBT Margin			2.54%
Operating Taxes	(21,000)	141,000	275,000
Tax Rate			33.29%
NOPAT	(473,000)	(381,000)	551,000
Net income	(180,000) -153.10%	339,000 -51.57%	700,000 41.41%
Dividends	(182,000)	(183,000)	(182,000)
Dividend yield	3.06%	2.76%	2.42%
Proceeds from repurchase of equity
BB yield
Debt
Debt current	3,455,000	3,119,000	3,254,000
Long-term debt	13,794,000	12,349,000	11,742,000
Deferred revenue	4,000	596,000	601,000
Other long-term liabilities	2,861,000	1,650,000	1,152,000
Net debt	5,983,000	2,246,000	455,000
Cash flow
Cash from operating activities	296,000	(916,000)	1,801,000
CAPEX	(2,636,000)	(1,014,000)	(727,000)
Cash from investing activities	(3,139,000)	(394,000)	35,000
Cash from financing activities	1,447,000	144,000	(793,000)
FCF	(3,242,000)	(2,945,000)	1,312,000
Balance
Cash	9,200,000	10,529,000	11,645,000
Long term investments	2,066,000	2,693,000	2,896,000
Excess cash	9,728,600	11,644,050	12,915,700
Stockholders' equity	20,307,000	36,473,000	36,287,000
Invested Capital	28,573,400	24,192,950	21,634,300
ROIC			2.49%
ROCE			2.33%
EV
Common stock shares outstanding	3,609	3,609	3,607
Price	1,649.00 -10.33%	1,839.00 -11.76%	2,084.00 -20.76%
Market cap	5,950,969 -10.35%	6,637,709 -11.69%	7,515,994 -20.51%
EV	11,933,969	24,977,709	23,909,994
EBITDA	965,000	1,260,000	2,412,000
EV/EBITDA	12.37	19.82	9.91
Interest	150,000	122,000	118,000
Interest/NOPBT			14.29%